US EditionBiotech Growth looks "susceptible" to merger approach after continuation vote shows dissent
Summary by QuotedData
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Biotech Growth looks "susceptible" to merger approach after continuation vote shows dissent
Biotech Growth (BIOG) passed its five-yearly continuation vote yesterday with 76.7% of votes in favour, but with over 23% of votes cast against the resolution, the £198m company could be vulnerable to consolidation in the sector, broker Deutsche Numis believes. Shares in the global biotech fund have slumped around 40% since the last vote in 2020, eradicating its previous sector-leading performance as sentiment turned bearish on smaller drug disc…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
